Letrozole vs MK-677
FDA Approved vs Well Studied
avoid Mechanism-based · 64% Both Letrozole and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Letrozole MK-677
Weight 285.30 Da 624.77 Da
Half-life ~2 days (48 hours) ~24 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) Non-peptide ghrelin receptor agonist
Key Benefits
Letrozole
01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Side Effects
Letrozole
Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
Fatigue and profound lethargy
Mood disturbance (depression, emotional flatness, irritability)
Decreased libido and sexual dysfunction
Hot flashes or flushing
Headache
Muscle aches and generalized pain
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Known hypersensitivity to letrozole or any excipients
Premenopausal women (unless under specialist care for fertility treatment)
Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
History of estrogen-crash-related adverse events with prior AI use
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Letrozole MK-677
Status FDA Approved Well Studied
References 5 studies 7 studies
Latest — July 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.